BST

SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron

Retrieved on: 
Wednesday, September 28, 2022

Participants received 25 mg/kg of SAB-176 diluted in normal saline or an equivalent volume of normal saline (placebo) in a single IV infusion.

Key Points: 
  • Participants received 25 mg/kg of SAB-176 diluted in normal saline or an equivalent volume of normal saline (placebo) in a single IV infusion.
  • SABs challenge trial for SAB-176 established proof of concept for this important clinical program, said Alexandra Kropotova, M.D., Chief Medical Officer at SAB.
  • The in vitro neutralizing capacity of SAB-185 was tested against 10 variant SARS-CoV-2 strains, including several Omicron variants.
  • This data suggests that SAB-185 may be an effective immunotherapy even in the presence of ongoing viral mutation, Dr. Kropotova said.

CARNIVAL CORPORATION & PLC TO PROVIDE THIRD QUARTER 2022 BUSINESS UPDATE

Retrieved on: 
Friday, September 23, 2022

Key Points: 

MIAMI, Sept. 23, 2022 /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) has scheduled a conference call with analysts for Friday, September 30, 2022, at 10 a.m. (EDT); 3 p.m. (BST) to provide a business update.

Buy-backs of shares in CoinShares International Limited and end of buyback period

Retrieved on: 
Friday, September 23, 2022

Following the above repurchases, the Company's holding of own shares as of 22 September 2022 amounts to 78,396 shares.

Key Points: 
  • Following the above repurchases, the Company's holding of own shares as of 22 September 2022 amounts to 78,396 shares.
  • The total number of shares in CoinShares amounts to 68,213,821.
  • CoinShares is publicly listed on the Nasdaq First North Growth Market under the ticker CS and the OTCQX under the ticker CNSRF.
  • For more information on CoinShares, please visit: https://coinshares.com
    This information is information that CoinShares International Limited is obliged to make public pursuant to the EU Market Abuse Regulation (596/2014).

Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium

Retrieved on: 
Thursday, September 22, 2022

Further information about the 12th International RSV Symposium can be found here .

Key Points: 
  • Further information about the 12th International RSV Symposium can be found here .
  • Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases.
  • Enantas research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV).
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.

Buy-backs of shares in CoinShares International Limited

Retrieved on: 
Thursday, September 22, 2022

Following the above repurchases, the Company's holding of own shares as of 21 September 2022 amounts to 75,996 shares.

Key Points: 
  • Following the above repurchases, the Company's holding of own shares as of 21 September 2022 amounts to 75,996 shares.
  • The total number of shares in CoinShares amounts to 68,213,821.
  • CoinShares is publicly listed on the Nasdaq First North Growth Market under the ticker CS and the OTCQX under the ticker CNSRF.
  • For more information on CoinShares, please visit: https://coinshares.com
    This information is information that CoinShares International Limited is obliged to make public pursuant to the EU Market Abuse Regulation (596/2014).

Polymetal: Half-year report for the six month ended 30 June 2022

Retrieved on: 
Thursday, September 22, 2022

Average realised gold and silver prices tracked market dynamics: gold price increased by 4% while silver price decreased by 14%.

Key Points: 
  • Average realised gold and silver prices tracked market dynamics: gold price increased by 4% while silver price decreased by 14%.
  • Gold sales decreased by 23% year-on-year to 456 Koz, while silver sales increased by 9% to 8.7 Moz.
  • Gold sales lagged production due to the bullion inventory accumulated across the Groups mines located in the Russian Federation.
  • Exchange rate dynamics will drive cost performance for H2 2022, as inflationary pressures in the Russian Federation cool down.

Polymetal: Offer to exchange certain shares currently affected by the EU asset freeze on NSD and Notice of General Meeting

Retrieved on: 
Thursday, September 22, 2022

On 3 June 2022, the EU imposed sanctions on the National Settlement Depository (NSD), which effectively blocked the operations between Euroclear and NSD.

Key Points: 
  • On 3 June 2022, the EU imposed sanctions on the National Settlement Depository (NSD), which effectively blocked the operations between Euroclear and NSD.
  • Consequently, the Board understands that approximately 11% of the Company's issued share capital may not be eligible for exchange under the Exchange Offer.
  • Under relevant Jersey laws, the manner in which the Exchange Offer is being conducted, requires the approval in general meeting of shareholders.
  • Further details of the exchange offer can be found in the combined shareholder circular and notice of General Meeting (the "Circular"), which has been published today.

Result of AGM

Retrieved on: 
Tuesday, September 20, 2022

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The Company's AGM was held today at 11.00 BST.
  • As at the close of business on 16 September 2022, the Company had 62,826,963 ordinary shares of 0.01 each in issue (with no shares held in treasury).
  • The final votes received in respect of each resolution put to the meeting were as set out below.

Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit

Retrieved on: 
Friday, September 16, 2022

VANCOUVER and MINNEAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.

Key Points: 
  • VANCOUVER and MINNEAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.
  • Neovascs President and Chief Executive Officer, Fred Colen, will be presenting at 11:10 am BST / 6:10 am ET on September 23, 2022.
  • Interested parties may view a live stream of Mr. Colens presentation by registering on the LSI website here .
  • Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace.

London Commodities Consultancy, CRU, To Spotlight Prescriptive Analytics for Monetizing Data at Big Data LDN, The UK’s Leading Data and Analytics Event

Retrieved on: 
Friday, September 16, 2022

Will Blake, Chief Technology Officer, will discuss how CRU uses prescriptive analytics and Decision Intelligence from Pyramid within its data analytics pipelines, better equipping customers to tackle key decisions within the commodity markets.

Key Points: 
  • Will Blake, Chief Technology Officer, will discuss how CRU uses prescriptive analytics and Decision Intelligence from Pyramid within its data analytics pipelines, better equipping customers to tackle key decisions within the commodity markets.
  • CRU is a leading London commodities consultancy, relied upon by its clients for expert insight and data on the global metals, mining and fertilizer industries.
  • Pyramid Analytics is the provider of the Pyramid Decision Intelligence Platform , the only purpose-built, unified Decision Intelligence Platform.
  • This panel discussion will take place from 12:40 p.m. 1:10 p.m. BST in the Modern Analytics Theatre at Big Data LDN.